Karyopharm Therapeutics Inc. Reports Q2 2026 Financial Results

What Happened Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2026 in an 8‑K filed August 13, 2026, and said it will hold a previously announced, publicly available conference call to discuss those results and other company updates. The company furnished the full press release as Exhibit 99.1 to the Form 8‑K.

Key Details

• Filing date: August 13, 2026; quarter covered: quarter ended June 30, 2026 (Q2 2026).
• Press release attached as Exhibit 99.1 to the Form 8‑K and incorporated by reference.
• Company will conduct a previously announced, publicly available conference call to discuss results and updates.
• The Form 8‑K notes that the furnished information (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings except where specifically noted.

Why It Matters For investors, this 8‑K signals the release of Karyopharm’s latest quarterly results and provides an opportunity to hear management’s discussion of performance and any strategic or operational updates on the conference call. Because the filing furnishes a press release (but states it is not “filed” under Section 18), investors should review the Exhibit 99.1 press release and listen to the call for details such as revenue, expenses, guidance changes, or program updates that could affect the stock.